139 related articles for article (PubMed ID: 14683454)
1. Biosafety of herpesvirus vectors.
Gogev S; Schynts F; Meurens F; Bourgot I; Thiry E
Curr Gene Ther; 2003 Dec; 3(6):597-611. PubMed ID: 14683454
[TBL] [Abstract][Full Text] [Related]
2. Development of herpesvirus-based episomally maintained gene delivery vectors.
Calderwood MA; White RE; Whitehouse A
Expert Opin Biol Ther; 2004 Apr; 4(4):493-505. PubMed ID: 15102599
[TBL] [Abstract][Full Text] [Related]
3. Herpesvirus saimiri: a potential gene delivery vector (review).
Whitehouse A
Int J Mol Med; 2003 Feb; 11(2):139-48. PubMed ID: 12525867
[TBL] [Abstract][Full Text] [Related]
4. Herpesvirus vectors come of age.
Hammerschmidt W
Curr Opin Mol Ther; 2000 Oct; 2(5):532-9. PubMed ID: 11249756
[TBL] [Abstract][Full Text] [Related]
5. [Gene therapy: new developments].
Mohr L; Geissler M
Praxis (Bern 1994); 2002 Dec; 91(51-52):2227-35. PubMed ID: 12564039
[TBL] [Abstract][Full Text] [Related]
6. Utilization of herpesviridae as recombinant viral vectors in vaccine development against animal pathogens.
Kamel M; El-Sayed A
Virus Res; 2019 Sep; 270():197648. PubMed ID: 31279828
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic analysis of herpesviruses and their potential use as vectors for gene therapy applications.
Cotter MA; Robertson ES
Curr Opin Mol Ther; 1999 Oct; 1(5):633-44. PubMed ID: 11249670
[TBL] [Abstract][Full Text] [Related]
8. Virological aspects on herpesvirus infections.
Lycke E
Scand J Infect Dis Suppl; 1985; 47():9-15. PubMed ID: 3006235
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs in large herpesvirus DNA genomes: recent advances.
Sorel O; Dewals BG
Biomol Concepts; 2016 Aug; 7(4):229-39. PubMed ID: 27544723
[TBL] [Abstract][Full Text] [Related]
10. Genetic requirements for the episomal maintenance of oncogenic herpesvirus genomes.
Collins CM; Medveczky PG
Adv Cancer Res; 2002; 84():155-74. PubMed ID: 11883526
[TBL] [Abstract][Full Text] [Related]
11. The diversity and unity of Herpesviridae.
Roizman B; Baines J
Comp Immunol Microbiol Infect Dis; 1991; 14(2):63-79. PubMed ID: 1935001
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus vectors for the nervous system.
Lilley CE; Branston RH; Coffin RS
Curr Gene Ther; 2001 Nov; 1(4):339-58. PubMed ID: 12109061
[TBL] [Abstract][Full Text] [Related]
13. Herpesviral vectors and their application in oncolytic therapy, vaccination, and gene transfer.
Bailer SM; Funk C; Riedl A; Ruzsics Z
Virus Genes; 2017 Oct; 53(5):741-748. PubMed ID: 28634751
[TBL] [Abstract][Full Text] [Related]
14. Herpesvirus saimiri-based gene delivery vectors.
Griffiths RA; Boyne JR; Whitehouse A
Curr Gene Ther; 2006 Feb; 6(1):1-15. PubMed ID: 16475942
[TBL] [Abstract][Full Text] [Related]
15. Potential Application of the CRISPR/Cas9 System against Herpesvirus Infections.
Chen YC; Sheng J; Trang P; Liu F
Viruses; 2018 May; 10(6):. PubMed ID: 29844277
[TBL] [Abstract][Full Text] [Related]
16. Biosafety of lentiviral vectors.
Debyser Z
Curr Gene Ther; 2003 Dec; 3(6):517-25. PubMed ID: 14683448
[TBL] [Abstract][Full Text] [Related]
17. The use of herpes simplex virus-based vectors for gene delivery to the nervous system.
Lachmann RH; Efstathiou S
Mol Med Today; 1997 Sep; 3(9):404-11. PubMed ID: 9302691
[TBL] [Abstract][Full Text] [Related]
18. Viral gene products actively promote latent infection by epigenetic silencing mechanisms.
Knipe DM; Raja P; Lee J
Curr Opin Virol; 2017 Apr; 23():68-74. PubMed ID: 28415052
[TBL] [Abstract][Full Text] [Related]
19. Engineering of cytomegalovirus genomes for recombinant live herpesvirus vaccines.
Mohr CA; Cîcîn-Saîn L; Wagner M; Sacher T; Schnee M; Ruzsics Z; Koszinowski UH
Int J Med Microbiol; 2008 Jan; 298(1-2):115-25. PubMed ID: 17702650
[TBL] [Abstract][Full Text] [Related]
20. Herpesvirus Latency: On the Importance of Positioning Oneself.
Lomonte P
Adv Anat Embryol Cell Biol; 2017; 223():95-117. PubMed ID: 28528441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
